271 related articles for article (PubMed ID: 17218487)
1. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases.
Vittal R; Zhang H; Han MK; Moore BB; Horowitz JC; Thannickal VJ
J Pharmacol Exp Ther; 2007 Apr; 321(1):35-44. PubMed ID: 17218487
[TBL] [Abstract][Full Text] [Related]
2. Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice.
Rhee CK; Lee SH; Yoon HK; Kim SC; Lee SY; Kwon SS; Kim YK; Kim KH; Kim TJ; Kim JW
Respiration; 2011; 82(3):273-87. PubMed ID: 21659722
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.
Daniels CE; Wilkes MC; Edens M; Kottom TJ; Murphy SJ; Limper AH; Leof EB
J Clin Invest; 2004 Nov; 114(9):1308-16. PubMed ID: 15520863
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia.
Vuorinen K; Gao F; Oury TD; Kinnula VL; Myllärniemi M
Exp Lung Res; 2007 Sep; 33(7):357-73. PubMed ID: 17849262
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
[TBL] [Abstract][Full Text] [Related]
6. A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate.
Bhattacharyya S; Ishida W; Wu M; Wilkes M; Mori Y; Hinchcliff M; Leof E; Varga J
Oncogene; 2009 Mar; 28(10):1285-97. PubMed ID: 19151753
[TBL] [Abstract][Full Text] [Related]
7. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
Akhmetshina A; Venalis P; Dees C; Busch N; Zwerina J; Schett G; Distler O; Distler JH
Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940
[TBL] [Abstract][Full Text] [Related]
8. Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury.
Vittal R; Horowitz JC; Moore BB; Zhang H; Martinez FJ; Toews GB; Standiford TJ; Thannickal VJ
Am J Pathol; 2005 Feb; 166(2):367-75. PubMed ID: 15681821
[TBL] [Abstract][Full Text] [Related]
9. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice.
Aono Y; Nishioka Y; Inayama M; Ugai M; Kishi J; Uehara H; Izumi K; Sone S
Am J Respir Crit Care Med; 2005 Jun; 171(11):1279-85. PubMed ID: 15735062
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate inhibits proliferation and exerts an antifibrotic effect in human breast stroma fibroblasts.
Gioni V; Karampinas T; Voutsinas G; Roussidis AE; Papadopoulos S; Karamanos NK; Kletsas D
Mol Cancer Res; 2008 May; 6(5):706-14. PubMed ID: 18505916
[TBL] [Abstract][Full Text] [Related]
12. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.
Pannu J; Asano Y; Nakerakanti S; Smith E; Jablonska S; Blaszczyk M; ten Dijke P; Trojanowska M
Arthritis Rheum; 2008 Aug; 58(8):2528-37. PubMed ID: 18668566
[TBL] [Abstract][Full Text] [Related]
13. Imatinib attenuates severe mouse dystrophy and inhibits proliferation and fibrosis-marker expression in muscle mesenchymal progenitors.
Ito T; Ogawa R; Uezumi A; Ohtani T; Watanabe Y; Tsujikawa K; Miyagoe-Suzuki Y; Takeda S; Yamamoto H; Fukada S
Neuromuscul Disord; 2013 Apr; 23(4):349-56. PubMed ID: 23313020
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway.
Terabe F; Kitano M; Kawai M; Kuwahara Y; Hirano T; Arimitsu J; Hagihara K; Shima Y; Narazaki M; Tanaka T; Kawase I; Sano H; Ogata A
Mod Rheumatol; 2009; 19(5):522-9. PubMed ID: 19568828
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate attenuates myocardial remodeling through inhibition of platelet-derived growth factor and transforming growth factor activation in a rat model of hypertension.
Jang SW; Ihm SH; Choo EH; Kim OR; Chang K; Park CS; Kim HY; Seung KB
Hypertension; 2014 Jun; 63(6):1228-34. PubMed ID: 24591339
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro.
Hinchcliff M; Huang CC; Ishida W; Fang F; Lee J; Jafari N; Wilkes M; Bhattacharyya S; Leof E; Varga J
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S86-96. PubMed ID: 22691216
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy.
van Steensel L; Paridaens D; Schrijver B; Dingjan GM; van Daele PL; van Hagen PM; van den Bosch WA; Drexhage HA; Hooijkaas H; Dik WA
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3091-8. PubMed ID: 19234339
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo.
Wang S; Wilkes MC; Leof EB; Hirschberg R
FASEB J; 2005 Jan; 19(1):1-11. PubMed ID: 15629889
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
Tipping AJ; Baluch S; Barnes DJ; Veach DR; Clarkson BM; Bornmann WG; Mahon FX; Goldman JM; Melo JV
Leukemia; 2004 Aug; 18(8):1352-6. PubMed ID: 15201856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
